Pertussis in adolescents and adults: Should we vaccinate?

Pediatrics

Volumn 115, Issue 6, 2005, Pages 1675-1684

  Lee, Grace M ^a,b   LeBaron, Charles ^c   Murphy, Trudy V ^c   Lett, Susan ^d   Schauer, Stephanie ^d   Lieu, Tracy A ^a,b  

^a HARVARD PILGRIM HEALTH CARE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CENTERS FOR DIS CONTR AND PREV   (United States)

^d MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Adolescent; Cost effectiveness; Immunization; Pertussis; Vaccine

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE; HEALTH HAZARD; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VACCINATION; COMPUTER SIMULATION; COST; COST OF ILLNESS; DECISION SUPPORT SYSTEM; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; ECONOMICS; FEMALE; IMMUNIZATION; MALE; NEWBORN; PREGNANCY; PROBABILITY; PUERPERIUM; THEORETICAL MODEL; UNITED STATES;

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE;

ADOLESCENT; ADULT; COMPUTER SIMULATION; COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; DIPHTHERIA-TETANUS VACCINE; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DISEASE SUSCEPTIBILITY; DISEASE TRANSMISSION, HORIZONTAL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MARKOV CHAINS; MODELS, THEORETICAL; POSTPARTUM PERIOD; PREGNANCY; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; WHOOPING COUGH;

EID: 23844552041     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-2509     Document Type: Article

References (44)

1. Farizo KM, Cochi SL, Zell ER, et al. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis. 1992;14:708-719
2. Yih WK, Lett SM, des Vignes FN et al. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J Infect Dis. 2000;182:1409-1416
3. Centers for Disease Control and Prevention. Pertussis: United States, 1997-2000. MMWR Morb Mortal Wkly Rep. 2002;51:73-76
4. Black S. Epidemiology of pertussis. Pediatr Infect Dis J. 1997;16(suppl):S85-S89
5. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis. 1999;28:1230-1237
6. Bisgard KM, Rhodes P, Connelly BL, et al. Pertussis vaccine effectiveness among children aged 6-59 months in the United States, 1998-2001. Presented at the 41st Annual Meeting of the Infectious Diseases Society of America; October 9-12, 2003; San Diego, CA
7. Centers for Disease Control and Prevention. National, state, and urban area vaccination levels among children aged 19-35 months: United States, 2002. MMWR Morb Mortal Wkly Rep. 2003;52:728-732
8. Mink CM, Cherry JD, Christenson P, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis. 1992;14:464-471
9. Nennig ME, Shinefield HR, Edwards KM, et al. Prevalence and incidence of adult pertussis in an urban population. JAMA. 1996;275:1672-1674
10. Wright SW, Edwards KM, Decker MD, et al. Pertussis infection in adults with persistent cough. JAMA. 1995;273:1044-1046
11. Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis. 2001;32:1691-1697
12. Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis. 1994;169:1297-1305
13. Skowronski DM, De Serres G, MacDonald D, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis. 2002;185:1448-1453
14. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed). 1988;296:612-614
15. Lambert HJ. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep. 1965;80:365-367
16. De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000;182:174-179
17. Thomas PF, McIntyre PB, Jalaludin BB. Survey of pertussis morbidity in adults in western Sydney. Med J Aust. 2000;173:74-76
18. Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004;39:1572-1580
19. Postels-Multani S, Schmitt HJ, Wirsing von Konig CH, et al. Symptoms and complications of pertussis in adults. Infection. 1995;23:139-142
20. Vitek CR, Pascual FB, Baughman AL, et al. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003;22:628-634
21. Tanaka M, Vitek CR, Pascual FB, et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA. 2003;290:2968-2975
22. Orenstein WA. Pertussis in adults: epidemiology, signs, symptoms, and implications for vaccination. Clin Infect Dis. 1999;28(suppl 2):S147-S150
23. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis. 1999;28(suppl 2):S112-S117
24. Nelson JD. The changing epidemiology of pertussis in young infants: the role of adults as reservoirs of infection. Am J Dis Child. 1978;132:371-373
25. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis. 1990;161:480-486
26. Mertsola J, Ruuskanen O, Eerola E, et al. Intrafamilial spread of pertussis. J Pediatr. 1983;103:359-363
27. Izurieta HS, Kenyon TA, Strebel PM, et al. Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis. 1996;22:503-507
28. Wirsing von Konig CH, Postels-Multani S, Bogaerts H, et al. Factors influencing the spread of pertussis in households. Eur J Pediatr. 1998;157:391-394
29. Deen JL, Mink CA, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis. 1995;21:1211-1219
30. National Advisory Committee on Immunization. Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003;29:1-9
31. De Serres G. An Advisory Committee Statement (ASC): National Advisory Committee on Immunization (NACI): statement on adult/ adolescent formulation of combined acellular pertussis, tetanus, and diphtheria vaccine. Can Commun Dis Rep. 2000;26:1-8
32. Campins-Marti M, Cheng HK, Forsyth K, et al. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine. 2001;20:641-646
33. Australian Government, Department of Health and Aging. The Australian Immunisation Handbook: fact sheet for immunisation providers. Available at: www.immunise.health.gov.au/nip/fact_provider.pdf. Accessed December 30, 2003
34. GlaxoSmithKline. GSK vaccines by country. Available at: www.worldwidevaccines.com/by_country/gsk_vaccines.asp. Accessed January 14, 2004
35. Chapman TM, Goa KL. Reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine (Boostrix). Drugs. 2003;63:1407-1413
36. Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine. 2000;19:628-636
37. Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine. 2000;18:2075-2082
38. Halperin SA, Smith B, Russell M, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine. 2000;18:1312-1319
39. Minh NN, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics. 1999;104(6). Available at: www.pediatrics.org/cgi/content/full/104/6/e70
40. Halperin SA, Smith B, Russell M, et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J. 2000;19:276-283
41. Ward J. The APERT Study. Presented at the National Consensus Conference on Pertussis; May 25-28, 2002; Toronto, Canada
42. Ward JI, APERT Study Group. Pertussis epidemiology and acellular pertussis vaccine efficacy in older children: NIH APERT Multicenter Pertussis Trial. Presented at the Pediatric Academic Societies Annual Meeting; April 28-May 1, 2001; Baltimore, MD
43. Thomas MG, Lambert HP. From whom do children catch pertussis? Br Med J (Clin Res Ed). 1987;295:751-752
44. Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis. 2003;14:196-198